Literature DB >> 17119039

Reproductive factors, oral contraceptive use, and human papillomavirus infection: pooled analysis of the IARC HPV prevalence surveys.

Salvatore Vaccarella1, Rolando Herrero, Min Dai, Peter J F Snijders, Chris J L M Meijer, Jaiye O Thomas, Pham Thi Hoang Anh, Catterina Ferreccio, Elena Matos, Hector Posso, Silvia de Sanjosé, Hai-Rim Shin, Sukhon Sukvirach, Eduardo Lazcano-Ponce, Guglielmo Ronco, Raj Rajkumar, You-Lin Qiao, Nubia Muñoz, Silvia Franceschi.   

Abstract

High parity, early age at first full-term pregnancy (FTP), and long-term oral contraceptive (OC) use increase cervical cancer risk, but it is unclear whether these variables are also associated with increased risk of acquisition and persistence of human papillomavirus (HPV) infection, the main cause of cervical cancer. Information on reproductive and menstrual characteristics and OC use were collected from 14 areas worldwide, among population-based, age-stratified random samples of women aged 15 years or older. HPV testing was done using PCR-based enzyme immunoassay. Unconditional logistic regression was used to estimate the odds ratios (OR) of being HPV-positive according to reproductive and menstrual factors and corresponding 95% confidence intervals (CI). When more than two groups were compared, floating CIs (FCI) were estimated. A total of 15,145 women (mean age, 40.9 years) were analyzed. Women with >or=5 FTPs (OR, 0.90; 95% FCI, 0.76-1.06) showed a similar risk of being HPV-positive compared with women with only one FTP (OR, 1.00; 95% FCI, 0.86-1.16). However, nulliparous women showed an OR of 1.40 (95% CI, 1.16-1.69) compared with parous women. Early age at first FTP was not significantly related to HPV positivity. HPV positivity was similar for women who reported >or=10 years of use of OCs (OR, 1.16; 95% FCI, 0.85-1.58) and never users of OCs (OR, 1.00; 95% FCI, 0.90-1.12). Our study suggests, therefore, that high parity, early age at first FTP, and long-term OC use are not associated with HPV prevalence, but rather these factors might be involved in the transition from HPV infection to neoplastic cervical lesions.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17119039     DOI: 10.1158/1055-9965.EPI-06-0556

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  40 in total

1.  A birth cohort analysis of the incidence of adenocarcinoma of the uterine cervix in the USA.

Authors:  Cairong Zhu; Bryan A Bassig; Yawei Zhang; Kunchong Shi; Peter Boyle; Ni Li; Tongzhang Zheng
Journal:  Eur J Cancer Prev       Date:  2015-05       Impact factor: 2.497

2.  HPV-DNA integration and carcinogenesis: putative roles for inflammation and oxidative stress.

Authors:  Vonetta M Williams; Maria Filippova; Ubaldo Soto; Penelope J Duerksen-Hughes
Journal:  Future Virol       Date:  2011-01-01       Impact factor: 1.831

3.  Short-term natural history of high-risk human papillomavirus infection in mid-adult women sampled monthly.

Authors:  Tsung-chieh Jane Fu; Long Fu Xi; Ayaka Hulbert; James P Hughes; Qinghua Feng; Stephen M Schwartz; Stephen E Hawes; Laura A Koutsky; Rachel L Winer
Journal:  Int J Cancer       Date:  2015-05-29       Impact factor: 7.396

4.  Epidemiology of Any and Vaccine-Type Anogenital Human Papillomavirus Among 13-26-Year-Old Young Men After HPV Vaccine Introduction.

Authors:  Emmanuel Chandler; Lili Ding; Pamina Gorbach; Eduardo L Franco; Darron A Brown; Lea E Widdice; David I Bernstein; Jessica A Kahn
Journal:  J Adolesc Health       Date:  2018-07       Impact factor: 5.012

5.  Human papillomavirus community in healthy persons, defined by metagenomics analysis of human microbiome project shotgun sequencing data sets.

Authors:  Yingfei Ma; Ramana Madupu; Ulas Karaoz; Carlos W Nossa; Liying Yang; Shibu Yooseph; Patrick S Yachimski; Eoin L Brodie; Karen E Nelson; Zhiheng Pei
Journal:  J Virol       Date:  2014-02-12       Impact factor: 5.103

6.  Prevalence, distribution and correlates of endocervical human papillomavirus types in Brazilian women.

Authors:  S A Lippman; M C A Sucupira; H E Jones; C G Luppi; J Palefsky; J H H M van de Wijgert; R L S Oliveira; R S Diaz
Journal:  Int J STD AIDS       Date:  2010-02       Impact factor: 1.359

7.  Human Papillomaviruses and genital co-infections in gynaecological outpatients.

Authors:  Rosita Verteramo; Alessandra Pierangeli; Emanuela Mancini; Ettore Calzolari; Mauro Bucci; John Osborn; Rosa Nicosia; Fernanda Chiarini; Guido Antonelli; Anna Marta Degener
Journal:  BMC Infect Dis       Date:  2009-02-12       Impact factor: 3.090

8.  A study of cervical intraepithelial neoplasia in pregnancy.

Authors:  Esha Khanuja; U K Ghosh; Parul Garg; Geetika Tomar; Molly Madan; Rani Bansal
Journal:  J Obstet Gynaecol India       Date:  2014-01-04

Review 9.  Human papillomavirus and HPV vaccines: a review.

Authors:  F T Cutts; S Franceschi; S Goldie; X Castellsague; S de Sanjose; G Garnett; W J Edmunds; P Claeys; K L Goldenthal; D M Harper; L Markowitz
Journal:  Bull World Health Organ       Date:  2007-09       Impact factor: 9.408

10.  Depot-medroxyprogesterone acetate and combined oral contraceptive use and cervical neoplasia among women with oncogenic human papillomavirus infection.

Authors:  Tiffany G Harris; Leslie Miller; Shalini L Kulasingam; Qinghua Feng; Nancy B Kiviat; Stephen M Schwartz; Laura A Koutsky
Journal:  Am J Obstet Gynecol       Date:  2009-05       Impact factor: 8.661

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.